Resolute Science is pioneering a new class of cancer therapeutics specifically designed for solid tumors, particularly those that are aggressive, difficult to treat, or rare. The company utilizes its proprietary MAC-TACs (Macrophage Targeted Conjugates) technology platform, which focuses on harnessing Tumor-Associated Macrophages (TAMs) to deliver cytotoxic agents directly to tumors. This innovative approach aims to enhance the safety and efficacy of cancer treatments by overcoming challenges such as tumor heterogeneity and drug resistance, which are common in traditional therapies. By developing biomarker-driven, synthetic molecules, Resolute Science aspires to create first-in-class therapeutics that can be applied across various cancer types, thereby addressing significant unmet medical needs in oncology.

The MAC-TAC platform enables Resolute Science to build a diverse pipeline of pan-cancer therapeutics, with ongoing programs targeting multiple solid tumor indications, including soft tissue sarcoma, breast cancer, melanoma, and lung cancer. The company's commitment to revolutionizing cancer treatment is reflected in its mission to provide well-tolerated, targeted therapies that improve patient outcomes and quality of life. By focusing on a universal drug-delivery system, Resolute Science aims to redefine the landscape of cancer care, offering hope to a substantial percentage of patients suffering from solid tumors.

United States

Resolute Science, Inc. is a pre-clinical, life science company aiming to develop a safe, effective, and novel therapeutic for the treatment of solid tumor cancers and other diseases.

Resolute Science

Company Details